SCHEMBL19635669

SCHEMBL19635669

N#CN1CC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)CCC12CC2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 0.66
LCK P06239 4/20 0.66
LYN P07948 3/20 0.66
NUDT14 O95848 2/20 0.62
NUDT5 Q9UKK9 2/20 0.62
SRC P12931 2/20 0.59
KDR P35968 2/20 0.59
TEK Q02763 1/20 0.59
EGFR P00533 4/20 0.57
ITK Q08881 3/20 0.57
TEC P42680 3/20 0.57
BMX P51813 3/20 0.57
TXK P42681 2/20 0.57
FGFR2 P21802 2/20 0.57
RIPK2 O43353 1/20 0.57
NR1I2 O75469 1/20 0.57
SLC22A3 O75751 1/20 0.57
LATS1 O95835 1/20 0.57
ABL1 P00519 1/20 0.57
ERBB2 P04626 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19635645 0.86 BTK (0.55) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635641 0.86 BTK (0.55) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635220 0.86 BTK (0.55) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635191 0.86 BTK (0.54) BTKLCKLYNNUDT14NUDT5
SCHEMBL17479837 0.84 BTK (0.72) BTKLCKLYNNUDT14NUDT5
SCHEMBL17479836 0.84 BTK (0.72) BTKLCKLYNNUDT14NUDT5
SCHEMBL17479775 0.82 BTK (0.74) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635199 0.82 BTK (0.67) BTKLCKLYNNUDT14NUDT5
SCHEMBL19635197 0.82 BTK (0.67) BTKLCKLYNNUDT14NUDT5
SCHEMBL28370698 0.82 BTK (0.67) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017198049-A1 PYRAZOLOPYRIMIDINE DERIVATIVE AS BTK INHIBITOR AND PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF 浙江予川医药科技有限公司 2017-11-23 WO disclosed